РЕШЕНИЕ ПРОБЛЕМЫ ХРОНИЧЕСКОЙ СИНЕГНОЙНОЙ ИНФЕКЦИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ
https://doi.org/10.15690/vsp.v13i1.913
Аннотация
Обсуждается сложная проблема антибактериальной терапии при синегнойной инфекции у больных муковисцидозом и ее исторические аспекты этой проблемы. Сравниваются различные лекарственные формы антибиотиков и приводятся дозы для терапии при муковисцидозе. Рассмотрены эффективность и безопасность ингаляционной формы раствора тобрамицина у пациентов с муковисцидозом, которые имеют хроническую синегнойную инфекцию. Показана целесообразность его назначения при первом высеве в мокроте синегнойной палочки с целью ее эрадикации, а также при хроническом высеве данного патогена для профилактики обострений бронхолегочного процесса, для улучшения функции легких и микробиологической стабильности. Приводятся собственные данные по применению препарата, доказывающие его хорошую переносимость и лечебный эффект.
Ключевые слова: дети; муковисцидоз; хроническая синегнойная инфекция; ингаляционная антибактериальная терапия; раствор тобрамицина
Об авторах
О. И. Симонова
Научный центр здоровья детей, Москва
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
Ю. В. Горинова
Научный центр здоровья детей, Москва
Россия
Россия
А. В. Лазарева
Научный центр здоровья детей, Москва
Россия
Россия
Л. К. Катосова
Научный центр здоровья детей, Москва
Россия
Россия
Н. И. Буркина
Научный центр здоровья детей, Москва
Россия
Россия
В. П. Черневич
Научный центр здоровья детей, Москва
Россия
Россия
Список литературы
1. Dodge J.A., Lewis P.A., Stanton M. et al. Cystic fibrosis mortality and survival in the United Kingdom, 1947 to 2003. Eur. Respir. J. 2006; 20: 4–51.
2. Krasovskii S.A., Chernyak A.V., Amelina E.L., Nikonova V.S., Voronkova A.Yu., Samoilenko V.A., Naumenko Zh.K., Kashirskaya N.Yu., Kapranov N.I., Sherman V.D., Shabalova L.A., Chistyakova V.P., Simonova O.I., Semykin S.Yu., Gorinova Yu.V., Avakyan L.V., Petrova P.N., Kusova Z.A., Usacheva M.V., Samsonova M.V. Dynamics of survival in patients with cystic fibrosis in Moscow and the Moscow region in 1992-2001 and 2002-2011. Pul'monologiya = Pulmonology. 2012; 3: 79–87.
3. Cystic Fibrosis Mutation Database. Available at: www.genet.sickkids.on.ca/cftr
4. Simonova O.I. Applications of dornase alfa in pediatric practice. Vopr. sovr. pediatrii = Current pediatrics. 2011; 10 (4): 145–152.
5. Armstrong D.S., Grimwood K., Carlin J.B. et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997; 156: 1197–1204.
6. Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus J. Cyst. Fibrosis. 2005; 4: 7–26.
7. Hoiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr. Scand. Suppl. 1982; 301: 33–54.
8. Botzenhart K., Doring G. Epidemiology and ecology of Pseudomonas aeruginosa. In: Pseudomonas aeruginosa as an opportunistic pathogen. M. Campa, M. Bendineli, H. Friedman (eds.). New York: Plenum Press. 1993. P. 1–18.
9. Doring G., Knight R., Bellon G. Immunology of cystic fibrosis. In: Cystic Fibrosis. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. M.E. Morlin, G.L. Hedges, A.L. Smith, J.L. Burns (eds.). J. Clin. Microbiol. 1994; 32: 1027–1030.
10. Sheppard M.N. The pathology of cystic fibrosis. In: Cystic Fibrosis. M.E. Hodson, D. Geddes (eds.). London: Chapman and Hall. 1995. P. 131–149.
11. Rosenfeld M., Ramsey B.W., Gibson R.L. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 2003; 9 (6): 492–497.
12. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997; 23 (5): 330–335.
13. Sharma G.D., Tosi M.F., Stern R.C., Davis P.B. Progression of pulmonary disease after disappearance of Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 169–173.
14. Corey M., Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am. J. Epidemiol. 1996; 143: 1007–1017.
15. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 1990; 116: 714–719.
16. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002; 34 (2): 277–287.
17. Matsui H., Grubb B.R., Tarran R. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of CF airways disease. Cell. 1998; 95: 1005–1015.
18. Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of CF patients. Clin. Invest. 2002; 109: 317–325.
19. Ramsey B.W., Pepe M.S., Quan J.M. et al Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–30.
20. Michel B.C. Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987. Chest. 1988; 94: 129–140.
21. Blumer J.L., Stern R.C., Klinger J.D. et al. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas. Am. J. Med. 1985; 79: 37–46.
22. Doring G., Conway S.P. et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur. Respir. J. 2000; 16: 749–767.
23. Smith M.J., White L.O., Bowyer H., Willis J., Hodson M.E. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob. Agents Chemother. 1986; 30: 614–616.
24. Hodson M.E., Roberts C.M., Butland R.J., Smith M.J. Oral ciprofloxacin compared with conventional intravenous treatment for P. aeruginosa infection in adults with cystic fibrosis. Lancet. 1987; 1: 235–237.
25. Shalit I., Stutman H.R., Marks M.I., Chartrand S.A., Hilman B.C Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am. J. Med. 1987; 82: 189–195.
26. Noah T.L., Ivins S.S., Abode K.A., Stewart P.W., Michelson P.H., Harris W.T., Henry M.M., Leigh M.W. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr. Pulmonol. 2010; 45 (3): 281–290.
27. Lillquist Y.P., Cho E., Davidson A.G. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J. Cyst. Fibrosis. 2011; 10 (3): 175–180.
28. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibrosis. 2013; 12 (1): 29–34.
29. Taccetti G., Bianchini E., Cariani L. et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax. 2012; 67 (10): 853–859.
30. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286–291.
31. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N. et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 2011; 165 (9): 847–856.
32. Kondrat'eva I.I., Kapranov N.I., Kashirskaya N.Yu., Sherman V.D. Cystic fibrosis in children and adults, a look into the future. Pediatriya im. G.N. Speranskogo – PEDIATRIYA. 2014; 92 (4): 142–144.
33. Simonova O.I., Lazareva A.V., Motuzova O.V., Ponomarenko O.A., Katosova L.K., Chistyakova V.P., Burkina N.I. New features of antibiotic therapy in acute and chronic respiratory diseases in children. Vopr. sovr. pediatrii = Current pediatrics. 2013; 12 (1): 123–130.
34. Lazareva A.V. Sovremennyi spektr vozbuditelei khronicheskogo vospaleniya pri boleznyakh organov dykhaniya u detei i optimizatsiya antibakterial'noi terapii. Avtoref. dis. … kand. med. nauk [Modern Range of Pathogens of Chronic Inflammation in Respiratory Diseases in Children and Optimization of Antibiotic Therapy. Author’s abstract]. Moscow, 2010. 24 p.
35. Poli G. et al. Clinical pharmacology study of Bramitob, a Tobramicyn Solution for Nebulization, in Comparison with Tobi. Pediatr. Drugs. 2007; 9 (Suppl. 1): 3–9.
36. Chuchalin A., Kapranov N. et al. A formulation of aerosolized tobramycin (BramitobR) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Drugs. 2007; 9 (Suppl. 1): 21–31.
37. Amelina E.L., Chuchalin A.G. Inhaled tobramycin in the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pul'monologiya = Pulmonology. 2009; 5: 120–126.
38. Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs. 2007; 9: 11–20.
39. Simonova O.I. nhalation therapy: what determines its effectiveness? Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (4): 126–131.
40. Khrushchev S.V., Simonova O.I. Fizicheskaya kul'tura detei s zabolevaniyami organov dykhaniya: uch. pos. dlya studentov vuzov [Physical Education of Children with Respiratory Diseases: Manual for Students]. Mоscow, Akademiya, 2006. 304 p.
Рецензия
Для цитирования:
Симонова О.И., Горинова Ю.В., Лазарева А.В., Катосова Л.К., Буркина Н.И., Черневич В.П. РЕШЕНИЕ ПРОБЛЕМЫ ХРОНИЧЕСКОЙ СИНЕГНОЙНОЙ ИНФЕКЦИИ У ДЕТЕЙ С МУКОВИСЦИДОЗОМ. Вопросы современной педиатрии. 2014;13(1):66-73. https://doi.org/10.15690/vsp.v13i1.913
For citation:
Simonova O.I., Gorinova Yu.V., Lazareva A.V., Katosova L.K., Burkina N.I., Chernevich V.P. SOLUTION OF THE PROBLEM OF PSEUDOMONAS INFECTION IN CHILDREN WITH CYSTIC FIBROSIS. Current Pediatrics. 2014;13(1):66-73. (In Russ.) https://doi.org/10.15690/vsp.v13i1.913
Просмотров: 968
Послать статью по эл. почте 
